The U.S. Food and Drug Administration (FDA) is taking a stronger approach toward supporting health goals in 2025 and beyond by setting the tone ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
A colorful ingredient you may find in your pantry or medicine cabinet is now banned by the Food and Drug Administration.
On January 16, the U.S. Food and Drug Administration (FDA) announced that it is revoking the authorization for use of FD&C Red No. 3 in ...
Rising diagnoses of certain cancers in people under 50 predate the rollout of COVID-19 vaccines by decades, undermining ...
Therapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from ...
Robert F. Kennedy Jr. has big plans for the FDA if he's confirmed as Secretary of Health and Human Services. FDA Commissioner ...
In the CodeBreaK 300 trial, sotorasib and panitumumab had better response rates and improved PFS vs standard-of-care ...
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...
On Wednesday, the Food and Drug Administration revoked authorization for the use of red dye No. 3 in food and ingested drugs.
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
The colorant was banned from cosmetics and non-oral medications years ago because a study showed it caused cancer in rats.